Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925209 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
NCT01925209 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 251 participants.
The verdict
NCT01925209, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
Study Summary
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).
Interventions
- DRUG Placebo
- DRUG BYM338/bimagrumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2013-09-26 |
| Est. Completion | 2016-01-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925209
The ClinicalTrials.gov registry entry for NCT01925209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01925209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01925209 about?
NCT01925209 is a clinical study titled "Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients". This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).
What is the current status of trial NCT01925209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2013-09-26. Estimated completion is 2016-01-06.
What interventions are being tested in trial NCT01925209?
The interventions under investigation include: Placebo (DRUG), BYM338/bimagrumab (DRUG).
Who is sponsoring clinical trial NCT01925209?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.